Erratum: Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2 (Molecular Pharmacology (2006) 69 (288–298) DOI: 10.1124/mol.105.016154);Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2

Molecular Pharmacology

Volumn 69, Issue 1, 2006, Pages 288-298

  Dasmahapatra, Girija ^a   Almenara, Jorge A ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; FLAVOPIRIDOL; HISTONE DEACETYLASE INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; VORINOSTAT;

ARTICLE; CELL DAMAGE; CELL DEATH; CELL PROTECTION; CELL STRAIN HL 60; CELL STRAIN U937; CLONOGENESIS; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIMERIZATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; EOSINOPHIL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LETHALITY; LEUKEMIA CELL; MITOCHONDRION; PHOSPHORYLATION; PRIORITY JOURNAL; WILD TYPE;

EID: 30044436031     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.016154retraction     Document Type: Erratum

References (40)

1. Achenbach TV, Muller R, and Slater EP (2000) Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. J Biol Chem 275:32089-32097.
2. Almenara J, Rosato R, and Grant S (2002) Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16:1331-1343.
3. Bjerling P, Silverstein RA, Thon G, Caudy A, Grewal S, and Ekwall K (2002) Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity. Mol Cell Biol 22:2170-2181.
4. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, and Guyotat D (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091-3096.
5. Carlson BA, Dubay MM, Sausville EA, Brizuela L, and Worland PJ (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973-2978.
6. Cartee L, Smith R, Dai Y, Rahmani M, Rosato R, Almenara J, Dent P, and Grant S (2002) Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways. Mol Pharmacol 61:1313-1321.
7. Chao SH and Price DH (2001) Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276:31793-31799.
8. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, and Korsmeyer SJ (2001) BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8:705-711.
9. Cress WD and Seto E (2000) Histone deacetylases, transcriptional control and cancer. J Cell Physiol 184:1-16.
10. Danial NN and Korsmeyer SJ (2004) Cell death: critical control points. Cell 116:205-219.
11. Decker RH, Wang S, Dai Y, Dent P, and Grant S (2002) Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. Cancer Biol Ther 1:136-144.
12. Deng X, Ito T, Carr B, Mumby M, and May WS Jr (1998) Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A. J Biol Chem 273:34157-34163.
13. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, and Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495-528.
14. Duan H, Heckman CA, and Boxer LM (2005) Histone deacetylase inhibitors down-regulate Bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25:1608-1619.
15. Edinger AL and Thompson CB (2004) Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 16:663-669.
16. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, et al. (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105:1768-1776.
17. Gojo I, Zhang B, and Fenton RG (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8:3527-3538.
18. Harris MH and Thompson CB (2000) The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 7:1182-1191.
19. Hu Y, Benedict MA, Wu D, Inohara N, and Nunez G (1998) Bcl-xL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 95:4386-4391.
20. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, and Pelicci PG (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71-76.
21. Jia L, Patwari Y, Srinivasula SM, Newland AC, Fernandes-Alnemri T, Alnemri ES, and Kelsey SM (2001) Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Oncogene 20:4817-4826.
22. Keogh SA, Walczak H, Bouchier-Hayes L, and Martin SJ (2000) Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Lett 471:93-98.
23. Kim WH, Park WB, Gao B, and Jung MH (2004) Critical role of reactive oxygen species and mitochondrial membrane potential in Korean mistletoe lectin-induced apoptosis in human hepatocarcinoma cells. Mol Pharmacol 66:1383-1396.
24. Kurdistani SK and Grunstein M (2003) Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 4:276-284.
25. Liu FT, Newland AC, and Jia L (2003) Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemia. Biochem Biophys Res Commun 310:956-962.
26. Redner RL and Liu JM (2005) Leukemia fusion proteins and co-repressor complexes: changing paradigms. J Cell Biochem 94:864-869.
27. Rosato RR, Dai Y, Almenara JA, Maggio SC, and Grant S (2004) Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 18:1780-1788.
28. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, and Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98:10833-10838.
29. Senderowicz AM (1999) Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investig New Drugs 17:313-320.
30. Takada Y and Aggarwal BB (2004) Flavopiridol inhibits NF-κB activation induced by various carcinogens and inflammatory agents through inhibition of IκBα kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2 and matrix metalloprotease-9. J Biol Chem 279:4750-4759.
31. Tang L, Boise LH, Dent P, and Grant S (2000) Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). Biochem Pharmacol 60:1445-1456.
32. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, and Grant S (1999) Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-xL, c-Jun and p21CIP1, but independent of p53. Oncogene 18:7016-7025.
33. Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, and Grant S (1997) Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-β-D-arabinofuranosylcytosine- induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol 52:1000-1009.
34. Wang S, Wang Z, Boise L, Dent P, and Grant S (1999a) Loss of the Bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochem Biophys Res Commun 259:67-72.
35. Wang S, Wang Z, Boise LH, Dent P, and Grant S (1999b) Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia 13:1564-1573.
36. Yamaguchi H and Wang HG (2002) Bcl-xL protects BimEL-induced Bax conformational change and cytochrome C release independent of interacting with Bax or BimEL. J Biol Chem 277:41604-41612.
37. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, and Wang X (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science (Wash DC) 275:1129-1132.
38. Yin DX and Schimke RT (1995) BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 55:4922-4928.
39. Yu C, Rahmani M, Conrad D, Subler M, Dent P, and Grant S (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102:3765-3774.
40. Zha H, Aime-Sempe C, Sato T, and Reed JC (1996) Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem 271:7440-7444.